That is interesting, it really points out how important the safety read out is however. Instead of measuring what symptoms subside to measure efficacy, the safety readout shows what symptoms or events don’t occur. This is important for mild cases because the worry is if their Covid progresses into a moderate or severe case. I think it is really important for cytodyn to do the M/M trial to see how early leronlimab shows action.